Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients

Veterinary Journal

Volumn 199, Issue 1, 2014, Pages 103-109

  Tomiyasu, Hirotaka ^a   Goto Koshino, Yuko ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

DNA methylation; Dog; Histone H3 acetylation; MDR1; Multidrug resistance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; TRICHOSTATIN A; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; DNA; HISTONE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; RHODAMINE 123;

ABCB1 GENE; ANIMAL CELL; ARTICLE; CANCER CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOG; DRUG SENSITIVITY; EXON; GENE; GENE EXPRESSION; GENETIC REGULATION; HISTONE ACETYLATION; LYMPHATIC SYSTEM TUMOR; NONHUMAN; PHENOTYPE; ACETYLATION; ANIMAL; DOG DISEASES; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LYMPHOMA; METABOLISM; METHYLATION; PHYSIOLOGY; TUMOR CELL LINE;

CANIS FAMILIARIS;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; LYMPHOMA; METHYLATION; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; RHODAMINE 123; RNA, MESSENGER;

EID: 84893006624     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.10.022     Document Type: Article

References (36)

1. Baker E.K., Johnstone R.W., Zalcberg J.R., El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005, 24:8061-8075.
2. Bergman P.J. Mechanisms of anticancer drug resistance. Veterinary Clinics of North America. Small Animal Practice 2003, 33:651-667.
3. Bergman P.J., Ogilvie G.K., Powers B.E. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996, 10:354-359.
4. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 2009, 55:611-622.
5. Chekhun V.F., Kulik G.I., Yurchenko O.V., Tryndyak V.P., Todor I.N., Luniv L.S., Tregubova N.A., Pryzimirska T.V., Montgomery B., Rusetskaya N.V., Pogribny I.P. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Letters 2006, 231:87-93.
6. Chen K.G., Wang Y.C., Schaner M.E., Francisco B., Duran G.E., Juric D., Huff L.M., Padilla-Nash H., Ried T., Fojo T., Sikic B.I. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Research 2005, 65:9388-9397.
7. David G.L., Yegnasubramanian S., Kumar A., Marchi V.L., De Marzo A.M., Lin X., Nelson W.G. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: Changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biology and Therapy 2004, 3:540-548.
8. Desiderato L., Davey M.W., Piper A.A. Demethylation of the human MDR1 5' region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somatic Cell and Molecular Genetics 1997, 23:391-400.
9. Dobson J.M., Blackwood L.B., McInnes E.F., Bostock D.E., Nicholls P., Hoather T.M., Tom B.D. Prognostic variables in canine multicentric lymphosarcoma. Journal of Small Animal Practice 2001, 42:377-384.
10. El-Osta A., Kantharidis P., Zalcberg J.R., Wolffe A.P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Molecular and Cellular Biology 2002, 22:1844-1857.
11. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
12. Gibney E.R., Nolan C.M. Epigenetics and gene expression. Heredity 2010, 105:4-13.
13. Hiraoka H., Minami K., Kaneko N., Shimokawa Miyama T., Okamura Y., Mizuno T., Okuda M. Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines. Journal of Veterinary Medical Science 2009, 71:769-777.
14. Kantharidis P., El-Osta A., deSilva M., Wall D.M., Hu X.F., Slater A., Nadalin G., Parkin J.D., Zalcberg J.R. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clinical Cancer Research 1997, 3:2025-2032.
15. Keller E.T., MacEwen E.G., Rosenthal R.C., Helfand S.C., Fox L.E. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 1993, 7:289-295.
16. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
17. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., Pogribny I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics 2008, 7:2152-2159.
18. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
19. Lee T.B., Park J.H., Min Y.D., Kim K.J., Choi C.H. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterology 2008, 8:33.
20. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
21. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: A review of recent developments and future prospects. The Veterinary Journal 2011, 188:34-38.
22. Matsuura S., Koto H., Ide K., Fujino Y., Setoguchi-Mukai A., Ohno K., Tsujimoto H. Induction of chemoresistance in a cultured canine cell line by retroviral transduction of the canine multidrug resistance 1 gene. American Journal of Veterinary Research 2007, 68:95-100.
23. Moore A.S., Cotter S.M., Rand W.M., Wood C.A., Williams L.E., London C.A., Frimberger A.E., L'Heureux D.A. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 2001, 15:348-354.
24. Moore A.S., Leveille C.R., Reimann K.A., Shu H., Arias I.M. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 1995, 13:475-479.
25. Nakaichi M., Taura Y., Kanki M., Mamba K., Momoi Y., Tsujimoto H., Nakama S. Establishment and characterization of a new canine B-cell leukemia cell line. Journal of Veterinary Medical Science 1996, 58:469-471.
26. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K., Kozuru M., Komatsu H., Ueda R., Kuwano M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998, 92:4296-4307.
27. O'Connor R. The pharmacology of cancer resistance. Anticancer Research 2007, 27:1267-1272.
28. Reed K., Hembruff S.L., Laberge M.L., Villeneuve D.J., Cote G.B., Parissenti A.M. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics 2008, 3:270-280.
29. Rutgen B.C., Hammer S.E., Gerner W., Christian M., de Arespacochaga A.G., Willmann M., Kleiter M., Schwendenwein I., Saalmuller A. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leukemia Research 2010, 34:932-938.
30. Skolnik J.M., Barrett J.S., Shi H., Adamson P.C. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemotherapy and Pharmacology 2006, 57:458-464.
31. Suzuki M.M., Bird A. DNA methylation landscapes: Provocative insights from epigenomics. Nature Reviews Genetics 2008, 9:465-476.
32. Tada Y., Wada M., Kuroiwa K., Kinugawa N., Harada T., Nagayama J., Nakagawa M., Naito S., Kuwano M. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clinical Cancer Research 2000, 6:4618-4627.
33. Tomiyasu H., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. Journal of Veterinary Medical Science 2010, 72:1165-1172.
34. Tomiyasu H., Watanabe M., Goto-Koshino Y., Fujino Y., Ohno K., Sugano S., Tsujimoto H. Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines. Leukemia and Lymphoma 2013, 54:1309-1315.
35. Xiao J.J., Huang Y., Dai Z., Sadee W., Chen J., Liu S., Marcucci G., Byrd J., Covey J.M., Wright J., et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. Journal of Pharmacology and Experimental Therapeutics 2005, 314:467-475.
36. Yamazaki J., Baba K., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K., Tsujimoto H. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Veterinary Immunology and Immunopathology 2008, 126:321-331.